Microbial and Biochemical Pharmacy —— Pharmacology

current position:

Home - Education - Ph.D. Supervisor - Microbial and Biochemical Pharmacy —— Pharmacology

XU Yanni




NameYanni Xu

DepartmentNational Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College

Tel: (8610)63180623

Email: xuyanni2010@imb.pumc.edu.cn

Education & Research Experience

2020/9- Now, Research professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2014/9-2020/9, Research associate professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2016/3-2017/3, Visiting Assistant professor, Medicine in the Aab Cardivascular Research Institute, University of Rochester

2010/9-2014/9, Research assistant professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2005/9-2010/7, Ph.D. in Microorganisms & Biochemical Pharmacy, Institute of Medicinal Biotechnology, Peking Union Medical College

2001/9-2005/7, Bachelor of Science in Pharmacology, Dept. of Pharmacy college, Shandong University

Research Field

Discovery of new target and lead compound for treating atherosclerosis

Research Interests

Dr. Xu’s research has been focused on discovery of novel drugs for treating anti-atherosclerosis and anti-osteoporosis. The specific ongoing projects in the lab are: 1) to establish in vitro high throughput screening method targeting potential drug targets; 2) to identify novel molecules for treating atherosclerosis and osteoporosis through screening; 3) to study the molecular mechanism of the lead compounds of anti-atherosclerosis, anti-osteoporosis.

Dr. Xu has gotten research support such as National Natural Science Foundation of China, the National Science and Technology Major Project of the Ministry of Science and Technology of China, CAMS Fundamental Research Funds, Beijing-Tianjin-Hebei Basic Research Cooperation Project, and so on.

Selected Publications

1) Suowen Xu#, Yanni Xu#, Peng Liu#, Shuya Zhang, Huan Liu, Spencer Slavin, Sandeep Kumar, Marina Koroleva, Jinque Luo, XiaoqianWu, Arshad Rahman, Jaroslav Pelisek, Hanjoong Jo, Shuyi Si, Clint L. Miller, and Zheng Gen Jin*. The novel coronary artery disease risk gene JCAD/KIAA1462 promotes endothelial dysfunction and atherosclerosis. European Heart Journal. (2019) 40, 2398–2408. (IF: 23.239)

2) Yanni Xu#, Chang Liu# , Xiaowan Han#, Xiaojian Jia, Yongzhen Li , Chao Liu , Ni Li , Lunming Liu , Peng Liu, Xinhai Jiang , Weizhi Wang, Xiao Wang, Yining Li, Mingzhu Chen, Jinque Luo, Xuan Zuo, Jiangxue Han, Li Wang , Yu Du , Yang Xu, Jian-Dong Jiang*, Bin Hong *, Shuyi Si*. E17241 as a Novel ABCA1 (ATP-Binding Cassette Transporter A1) Upregulator Ameliorates Atherosclerosis in Mice. Arterioscler Thromb Vasc Biol. 2021 Jan 14; doi: 10.1161/ATVBAHA.120.314156. PMID: 33441025.

3) Jinque Luo#, Xiao Wang#, Xinhai Jiang, Chao Liu, Yongzhen Li, Xiaowan Han, Xuan Zuo, Yining Li, Ni Li, Yanni Xu*, Shuyi Si*, Rutaecarpine derivative R3 attenuates atherosclerosis via inhibiting NLRP3 inflammasome-related inflammation and modulating cholesterol transport. FASEB J. 2020 Jan;34(1):1398-1411. doi: 10.1096/fj.201900903RRR. Epub 2019 Dec 1.

4) Xinhai Jiang, Yining Li, Weizhi Wang, Xiaowan Han, Jiangxue Han, Mingzhu Chen, Jing Zhang, Chenyin Wang, Shunwang Li, Jinque Luo, Xiao Wang, Yang Xu, Yanni Xu*, Jingcai Cheng*, Shuyi Si*, Nrf2 activator JC-5411 inhibits atherosclerosis through suppression of inflammation and regulation of lipid metabolism, Front Pharmacol. 16 November 2020, https://doi.org/10.3389/fphar.2020.532568

5) Dongsheng Li#, Chao Liu#, Xinhai Jiang, Yuan Lin, Jing Zhang, Yan Li, Xuefu You, Wei Jiang, Minghua Chen*, Yanni Xu*, Shuyi Si*, Design, Synthesis, and Evaluation of Substituted 2-acylamide-1,3-benzo[d]zole Analogues as Agents against MDR- and XDR-MTB, European Journal of Medicinal Chemistry, 2021 Jan 1;209:112898. doi: 10.1016/j.ejmech.2020.112898. Epub 2020 Oct 10.

6) Ni Li#, Xiao Wang, Peng Liu, Duo Lu, Wei Jiang, Yanni Xu*, Shuyi Si*, E17110 promotesreversecholesteroltransport with liver X receptor β agonist activity in vitro. Acta Pharmaceutica Sinica B, 2016;6(3):198–204.

7) Yanni Xu#, Suowen Xu#, Peng Liu#, Marina Koroleva, Shuya Zhang, Shuyi Si, ZhengGen Jin*. Suberanilohydroxamic Acid as a Pharmacological Kruppel-Like Factor 2 Activator That Represses Vascular Inflammation and Atherosclerosis, J Am Heart Assoc, 2017.11.30, 6(12)

8) Yanni Xu#, Qi Liu#, Yang Xu, Chang Liu, Xiao Wang, Xiaobo He, Ningyu Zhu, Jikai Liu, Yexiang Wu, Yongzhen Li, Ni Li, Tingting Feng, Fangfang Lai, Murui Zhang, Bin Hong,* Jian-Dong Jiang,* Shuyi Si.* Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through up-regulating ABCA1 and SR-BI within RCT. Journal of lipid research. 2014 Aug;55(8):1634-47.

9) Tingting Feng#, Peng Liu#, Xiao Wang, Jinque Luo, Xuan Zuo, Xinhai Jiang, Chang Liu, Yongzhen Li, Ni Li, Minghua Chen, Ningyu Zhu, Xiaowan Han, Chao Liu, Yanni Xu*, Shuyi Si*. SIRT1 activator E1231 protects from experimental atherosclerosis and lowers plasma cholesterol and triglycerides by enhancing ABCA1 expression. Atherosclerosis. 2018 Jul; 274:172-181.

10) Xu S#, Xu Y, Yin M, Zhang S, Liu P, Koroleva M, Si S, Little PJ, Pelisek J, Jin ZG*. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. Theranostics. 2018 Apr 30;8(11):3007-3021. doi: 10.7150/thno.21966. eCollection 2018.

11) Niu N#, Xu S#*, Xu Y, Little PJ, Jin ZG*. Targeting Mechanosensitive Transcription Factors in Atherosclerosis. Trends Pharmacol Sci. 2019 Feb 27. pii: S0165-6147(19)30035-5. doi: 10.1016/j.tips.2019.02.004.

12) Yanni Xu#, Peng Liu#, Suowen Xu, Marina Koroleva, Shuya Zhang, Shuyi Si*, Zheng Gen Jin*. Tannic acid as a plant-derived polyphenol exerts vasoprotection via enhancing KLF2 expression in endothelial cells. Scientific Reports. 2017 Jul 27;7(1):6686.

13) Chang Liu#, Tingting Feng, Ningyu Zhu, Peng Liu, Xiaowan Han, Minghua Chen, Xiao Wang, Ni Li, Yongzhen Li, Yanni Xu*, Shuyi Si*. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis, Scientific Reports. 2015.4.1, 5: 9530.

14) Ni Li, Xiao Wang, Yongzhen Li, Tingting Feng, Chang Liu, Yanni Xu*, Shuyi Si*. Identification of a novel selective agonist for Liver X Receptor α (LXRα) via Screening. Biochemical pharmacology. 92 (2014) 438–447.

15) Yongzhen Li, Tingting Feng, Chang Liu, Ni Li, Dongsheng Li, Minghua Chen, Xiao Wang, Yanni Xu*, Shuyi Si*. Optimization of Rutaecarpine as ABCA1 up-regulators for treating Atherosclerosis. ACS Medicinal Chemistry Letters. 2014 Jun 24;5(8):884-8.

16) Yanni Xu#, Juan Wang#, Yi Bao, Wei Jiang, Lian Zuo, Danqing Song, Bin Hong, Shuyi Si. Discovery of two novel antagonists of the Scavenger Receptor CD36 through a high throughput screening model. Analytical Biochemistry. 400 (2010) 207–212.

Awards and Honors

2019.4, The 3rd prize of Young Scientist Innovation Forum Report of PUMC.

2015.2, SLAS Tony B. Academic Travel Award to SLAS2015, Washington, D.C.

2015.4, The 1st prize of the outstanding poster winner of 2015 SLAS Asia Conference and Exhibition,

2013, Excellent papers, Twelfth National Conference of antibiotics.

2013, Excellent papers, Acta Pharmaceutica Sinica.

Academic Appointments

Member of the expert group on the reverse cholesterol transport of Chinese atherosclerosis professional committee of the Chinese Society of Pathophysiology.